Difficulty: Medium
Average Score: 77%
Practice
A 3-year child presents in emergency department with history of difficulty in breathing for 1 day. He is diagnosed as having asthma as he had similar episodes on and off relieved with nebulization with beta agonists. In emergency department he is given nebulization with beta agonists, injection methylprednisolone but did not respond. Which of following is the next best treatment option?
Correct answer
A
Rationale
In the scenario presented, the correct next best treatment option is A) IV magnesium sulphate. IV magnesium sulfate is indicated in cases of severe acute asthma exacerbation that is unresponsive to initial bronchodilator therapy. Magnesium sulfate acts as a bronchodilator and has been shown to help relax smooth muscle in the airways, thereby improving airflow.
IV epinephrine (option B) is not recommended in the treatment of acute asthma exacerbation as it can lead to adverse cardiovascular effects and is not considered a first-line therapy. IM epinephrine (option C) is also not recommended due to the risk of systemic side effects and potential for delayed response compared to other treatment options. IV aminophylline (option D) is no longer considered a first-line treatment for acute asthma exacerbation due to its narrow therapeutic window, potential for toxicity, and availability of safer and more effective treatment options.
Educationally, understanding the appropriate management of acute asthma exacerbation in pediatric patients is crucial for healthcare providers working in emergency departments or pediatric settings. Knowing when to escalate treatment to IV magnesium sulfate in cases of severe exacerbation is essential for improving patient outcomes and preventing complications. It is important to stay updated on current guidelines and evidence-based practices to provide optimal care for pediatric patients with respiratory conditions.
IV epinephrine (option B) is not recommended in the treatment of acute asthma exacerbation as it can lead to adverse cardiovascular effects and is not considered a first-line therapy. IM epinephrine (option C) is also not recommended due to the risk of systemic side effects and potential for delayed response compared to other treatment options. IV aminophylline (option D) is no longer considered a first-line treatment for acute asthma exacerbation due to its narrow therapeutic window, potential for toxicity, and availability of safer and more effective treatment options.
Educationally, understanding the appropriate management of acute asthma exacerbation in pediatric patients is crucial for healthcare providers working in emergency departments or pediatric settings. Knowing when to escalate treatment to IV magnesium sulfate in cases of severe exacerbation is essential for improving patient outcomes and preventing complications. It is important to stay updated on current guidelines and evidence-based practices to provide optimal care for pediatric patients with respiratory conditions.